drugset / Trial / NCT01372930

Etanercept Treating Patient With Acute ST Segment Elevated Myocardial Infarction

NCT01372930

Phase 4 Unknown 200 enrolled Xijing Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Our aim is to observe whether anti-TNF-alpha regimen will effect serum adiponectin concentration after myocardial infarction/reperfusion and also beneficial for the patients undergoing percutaneous coronary intervention (PCI).

Timeline

Start
2010-04
Primary completion
2014-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg Subcutaneous

Indications